ArticlePLoS pathogens2026
Cyclic di-GMP directly reprograms the multidrug resistance machinery via UspG-mediated sequestration of RamR in Klebsiella.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The integration of environmental cues to counter selective pressures is crucial for the epidemiological success of major human pathogens. Klebsiella pneumoniae poses an increasing critical public health threat due to its high biofilm forming capacity and adaptive antimicrobial resistance. While the second messenger cyclic di-GMP (c-di-GMP) is a key regulator of bacterial cellular physiological adaptations, its downstream effectors that control antibiotic resistance remain unknown in K. pneumoniae. Unlike c-di-GMP metabolizing enzymes, which contain highly conserved GGDEF or EAL domains, effectors enable signal transduction through structurally heterogeneous sensing domains that defy homology-based prediction. Here, we identified that upon the elevation of intracellular c-di-GMP levels induced by antibiotic treatmen, the universal stress protein UspG (AVR78_17055) serves as a cryptic, direct c-di-GMP effector in extended-spectrum beta-lactamase (ESBL)-producing strain K. quasipneumoniae ATCC 700603. Utilizing site-directed mutagenesis and EMSA, we demonstrate that UspG senses elevated intracellular c-di-GMP levels, thereby promoting biofilm formation, via N39 and K116 residues. Mechanistically, c-di-GMP binding enhances the binding affinity of UspG to the transcriptional repressor RamR. This specific protein sequestration antagonizes RamR, a transcriptional repressor that regulates RamA expression, thereby derepressing the ramA locus and unleashing a regulatory program that fortifies lipid A biosynthesis, upregulates multidrug efflux pumps expression, and promotes biofilm development. Importantly, this c-di-GMP-UspG axis is not restricted to ESBL-producing lineages. Through mutagenesis verification, we discovered similar phenotypic dependency in hypervirulent K. pneumoniae ATCC 43816. These findings indicate that UspG is functionally conserved across Enterobacteriaceae. By elucidating how Klebsiella exploits UspG to bridge intracellular nucleotide signaling with acute environmental adaptation, our study provides a new therapeutic target for recalcitrant Klebsiella infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.